Novo Nordisk's Victoza receives first approval –in the EU
This article was originally published in Scrip
Executive Summary
Novo Nordisk's GLP-1 analogue Victoza (liraglutide) has received marketing authorisation in the EU – its first approval – for the treatment of type 2 diabetes. The approval follows a CHMP positive opinion of Victoza in April (scripnews.com, April 24th, 2009).